Full Press Release Details
SAN DIEGO and INDIANAPOLIS , June 24, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced results from an analysis designed to evaluate the cost-effectiveness of insulin lispro mix 75/25 and insulin lispro mix 50/50 versus long-acting insulin analog (LAIA).
The analysis indicated that for patients with type 2 diabetes who do not experience frequent hypoglycemia, insulin lispro premixed insulin analogs are likely to be cost-effective when compared to LAIA in the long-term treatment of type 2 diabetes. The results were presented today at the Association's 71st Scientific Sessions in San Diego, CA. The study also will be featured at the President's Poster Session, a showcase featuring 100 outstanding posters selected by the Scientific Sessions Meeting Planning Committee.
The analysis further quantified a recent meta-analysis conducted by the Agency for Healthcare Research and Quality (AHRQ), which assessed the relative effectiveness and safety of premixed analog insulin and LAIA, finding that premixed insulin analogs may provide tighter glycemic control than long-acting alternatives.
A validated diabetes model was used to compare the cost effectiveness of insulin lispro premixed insulin analogs versus LAIA from a U.S. healthcare payer perspective.
Insulin lispro premixed insulin analogs were associated with improvements in both life expectancy (+0.07 and +0.09 years, respectively) and quality-adjusted life expectancy (+0.07 quality-adjusted life years [QALYs] and +0.08 QALYs, respectively) when compared with LAIA. These clinical benefits were accompanied by increases in direct lifetime costs of $1,724 and $1,720 relative to LAIA, yielding incremental cost-effectiveness ratios of $28,580 and $23,150 per QALY gained for the premixed insulin analogs versus LAIA, respectively.
To calculate the costs, the base case analysis was run over a time horizon of 35 years to capture all relevant long-term complications and associated costs and assess their impact on life expectancy and quality-adjusted life expectancy. Future cost and clinical outcomes were discounted at 3 percent annually.
Sensitivity analyses were performed to investigate the effect of time horizon, discounting, minor hypoglycemia rates, diabetes complication costs, insulin costs and method of quality-adjusted life expectancy estimation on outcomes.
Study limitations included variability in the quality of the reported data on hypoglycemia rates from the studies used for the meta-analysis. Additionally, the meta-analysis represented data from short-term clinical trials, which was extrapolated to make long-term projections.
"We know that 28 percent of people with type 2 diabetes use insulin to manage their diabetes, and once insulin treatment begins, it could be a life-long part of their disease management," said Dana Hardin , MD, a clinical research physician at Lilly. "These study findings are encouraging because, while not all patients are candidates for premixed insulin, those who are may have another viable and cost-effective treatment option."
Diabetes affects more than 25 million people in the U.S.(1) and is the fifth leading cause of death by disease. In 2007, the most recent year for which data is available, costs for diabetes were approximately $174 billion dollars .(2)
Who should use insulin lispro premixed insulin analogs?
Insulin lispro premixed insulin analogs are used to treat people with diabetes for the control of high blood sugar.
Important Safety Information for insulin lispro, insulin lispro mix 75/25, and insulin lispro mix 50/50
Who should not take Insulin lispro, insulin lispro mix 75/25, or insulin lispro mix50/50?
What is the most important information I should know about insulin lispro, insulin lispro mix 75/25, and insulin lispro mix 50/50?
Before using Insulin lispro, insulin lispro mix 75/25, or insulin lispro mix50/50, what should I tell my healthcare providers?
Tell your healthcare providers:
How should I use insulin lispro, insulin lispro mix 75/25, or insulin lispro mix 50/50 ?
What are the possi ble side effects of Insulin lispro, insulin lispro mix 75/25, or insulin lispro mix 50/50?
You are encouraged to report negative side effects of Prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
How should I store insulin lispro, insulin lispro mix 75/25, and insulin lispro mix 50/50?
Insulin lispro, insulin lispro mix 75/25, and insulin lispro mix 50/50 are available by prescription only.
For more information about insulin lispro, insulin lispro mix 75/25 and insulin lispro mix 50/50, please see the Full Prescribing Information ( http://pi.lilly.com/us/insulin lispro-pen-pi.pdf , http://pi.lilly.com/us/insulin lispro7525-pi.pdf , http://pi.lilly.com/us/insulin lispro5050-pi.pdf ) and Patient Information ( http://pi.lilly.com/us/insulin lispro-pen-ppi.pdf , http://pi.lilly.com/us/insulin lispro7525-pen-ppi.pdf , http://pi.lilly.com/us/insulin lispro5050-pen-ppi.pdf ).
Please see full user manual that accompanies your pen.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN , Lilly provides answers — through medicines and information — for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com .
About Lilly Diabetes
For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world's first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy — practical tools, education, and support programs to help overcome barriers to success along the diabetes journey. At Lilly, the journeys of each person living with or treating diabetes inspire ours. For more information, visit www.lillydiabetes.com .
Presentation 418-PP
(1) American Diabetes Association. Diabetes Statistics. http://www.diabetes.org/diabetes-basics/diabetes-statistics/ . Accessed June 1, 2011 . < Section 1, Paragraph 1, Line 1> (2) American Diabetes Association. Direct and Indirect Costs of Diabetes in the United States . http://www.diabetes.org/how-to-help/action/resources/cost-of-diabetes.html . Accessed June 1, 2011 . < Section 2, Paragraph 4, Line 1>
SOURCE Eli Lilly and Company